Journal
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume 52, Issue 5, Pages 606-608Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/00365521.2017.1280530
Keywords
Rituximab; anti-CD20 therapy; inflammatory bowel disease; Crohn's disease; lymphoma
Categories
Ask authors/readers for more resources
The use of rituximab has significantly improved outcomes in patients with haematological malignancies and autoimmune disease. There are reports of rituximab-associated ulcerative colitis; however, we report for the first time, two cases of rituximab-induced Crohn's disease in elderly patients treated for lymphoma. Both patients had evidence of inflammation, ulceration, and granulomas consistent with Crohn's disease, and responded well to immunosuppression. The association of rituximab and ileocolitis suggests a protective effect of CD20+ lymphocytes in the gut, and implicates their depletion to the development and exacerbation of inflammatory bowel disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available